Live Analyst Rating Changes 3274 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Michael Luo CFA
CLSA
Michael Luo CFA
CLSA
Wall Street Analyst
Not yet ranked — too few measurable calls.
100%
Success Rate
+17.7%
Average Return
1 of 1 calls profitable · +21.1% vs benchmark
📈 Across the calls we could measure, roughly 100% of Michael Luo CFA's ratings turned a profit when each position was held for 1 year — averaging +17.7% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

15 Buy 0 Hold 0 Sell
Michael's Stock Coverage 17 ratings · 2026-06-28
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
CRL
Charles River Labs
 May 29, 2026 BUY Strong Buy
-4.0% avg upside
34 analysts
$219.00
1.61% Upside
 +17.7%
HK:3347
Hangzhou Tigermed Consulting Co., Ltd. Class H
 Oct 30, 2025 BUY Strong Buy
+59.0% avg upside
2 analysts
$52.10
53.24% Upside
 ·
HK:2359
WuXi AppTec Co., Ltd. Class H
 Oct 27, 2025 BUY Strong Buy
+5.9% avg upside
2 analysts
$138.60
4.74% Downside
 ·
HK:6078
Hygeia Healthcare Holdings Co., Ltd.
 Aug 29, 2025 BUY Strong Buy
+106.4% avg upside
2 analysts
$17.00
95.03% Upside
 ·
HK:1951
Jinxin Fertility Group Ltd.
 Aug 28, 2025 BUY Strong Buy
+73.4% avg upside
2 analysts
$3.50
77.70% Upside
 ·
HK:6821
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
 Aug 27, 2025 BUY Strong Buy
-6.2% avg upside
2 analysts
$110.20
0.89% Downside
 ·
HK:2269
Wuxi Biologics (Cayman)
 Aug 25, 2025 BUY Buy
+14.3% avg upside
4 analysts
$42.60
29.00% Upside
 ·
HK:0867
China Medical System Holdings
 Aug 20, 2025 BUY Strong Buy
+68.7% avg upside
2 analysts
$15.60
57.08% Upside
 ·
HK:3692
Hansoh Pharmaceutical Group Company Limited
 Aug 20, 2025 BUY Strong Buy
+37.6% avg upside
5 analysts
$43.10
50.32% Upside
 ·
HK:1177
Sino Biopharmaceutical
 Jul 21, 2025 BUY Strong Buy
+87.7% avg upside
6 analysts
$9.20
115.91% Upside
 ·
JP:7747
Asahi Intecc Co
 May 20, 2025 BUY Strong Buy
-6.2% avg upside
3 analysts
$2490.00
33.15% Downside
 ·
JP:4543
Terumo
 May 20, 2025 BUY Strong Buy
+70.3% avg upside
5 analysts
$3230.00
45.98% Upside
 ·
HK:2273
Gushengtang Holdings Limited
 Apr 08, 2025 BUY Strong Buy
+67.0% avg upside
1 analyst
$42.00
67.03% Upside
 ·
CH:LONN
Lonza Group Ltd
 Dec 12, 2024 BUY Strong Buy
+19.5% avg upside
20 analysts
$723.00
35.15% Upside
 ·
JP:7733
Olympus
 Nov 13, 2024 BUY Strong Buy
+55.9% avg upside
4 analysts
$2850.00
69.16% Upside
 ·
HK:6127
JOINN Laboratories (China) Co., Ltd. Class H
 Apr 10, 2024 BUY Strong Buy
-46.0% avg upside
2 analysts
$11.00
39.23% Downside
 ·
HK:1521
Frontage Holdings Corp.
 Apr 04, 2024 SELL Sell
+65.7% avg upside
2 analysts
$1.50
74.35% Upside
 ·
🔒 12 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Michael Luo CFA — Frequently Asked Questions
How accurate are Michael Luo CFA's stock ratings?
Based on the calls 13Foresight could measure, about 100% of Michael's ratings were profitable over a one-year hold, with an average return of +17.7% per rating, or +21.1% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Michael ranked on 13Foresight?
Michael Luo CFA is currently ranked unranked . Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Michael cover?
Michael most recently has ratings on CRL, HK:3347, HK:2359, HK:6078, HK:1951, HK:6821, HK:2269, HK:0867, HK:3692, HK:1177, JP:7747, JP:4543 and 5 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.